RightFit
Not yet recruitingPhase 2

A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 75 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how well LY4086940 works and how safe it is compared with a placebo (a treatment with no active drug). It is for people without type 2 diabetes who have obesity or are overweight with a weight-related health problem. The study lasts about 58 weeks.

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition. Participation in the study will last about 58 weeks.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Must meet the entry rules in the main study plan, CWMM (NCT06143956).

Who can't join

  • Meet any exclusion rules in the main study plan, CWMM (NCT06143956).
  • Have ever been diagnosed with type 1, type 2, or a rare form of diabetes. Diabetes during pregnancy is an exception.
  • Have a lab test result that suggests diabetes.
  • Had a heart attack, stroke, unstable angina (heart-related chest pain), or a hospital stay for heart failure in the 6 months before screening.
  • You or a parent, sibling, or child has a history of multiple endocrine neoplasia type 2A or 2B (conditions that cause tumors in hormone-making glands), thyroid C-cell hyperplasia (too many of certain thyroid cells), or medullary thyroid carcinoma (a type of thyroid cancer).
  • Used medicines or other remedies that promote weight loss in the 6 months before screening. This includes prescription and over-the-counter drugs, herbs, and nutrition supplements.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Meet inclusion criteria under Master Protocol CWMM (NCT06143956) Exclusion Criteria: In addition to exclusion criteria under Master Protocol CWMM (NCT06143956) * Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes * Have a laboratory value suggestive of diabetes * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have a known personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma. * Within 6 months prior to screening, have taken medications (prescribed or over the counter) or alternative remedies (including herbal or nutritional supplements) that promote weight loss

Study sites (39)

AZ

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa · Chandler, AZ 85225Yessica Sachdeva · Principal investigatorMore trials in Chandler
  • Headlands Research - Scottsdale · Scottsdale, AZ 85260Benjamin Clark · Principal investigatorMore trials in Scottsdale
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson · Tucson, AZ 85712Anita Kohli · Principal investigatorMore trials in Tucson

CA

CT

FL

IA

ID

  • Medical Research Partners · Ammon, ID 83406Joseph Moore · Principal investigatorMore trials in Ammon

IL

  • Great Lakes Clinical Trials - Ravenswood · Chicago, IL 60640Rupal Trivedi · Principal investigatorMore trials in Chicago

KS

  • Cotton O'Neil Diabetes & Endocrinology · Topeka, KS 66606susan brian · Principal investigatorMore trials in Topeka

MA

MI

  • Headlands Research - Detroit · Southfield, MI 48034Christopher Romero · Principal investigatorMore trials in Southfield
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division · Troy, MI 48098Neil Fraser · Principal investigatorMore trials in Troy

MO

NC

NV

NY

OH

SC

TN

TX

  • IMA Clinical Research Austin · Austin, TX 78745Nomita Kim · Principal investigatorMore trials in Austin
  • Velocity Clinical Research, Dallas · Dallas, TX 75230Dan Lender · Principal investigatorMore trials in Dallas
  • FutureSearch Trials of Dallas · Dallas, TX 75251Michael Downing · Principal investigatorMore trials in Dallas
  • Endeavor Clinical Trials · San Antonio, TX 78240Nitendra Agarwal · Principal investigatorMore trials in San Antonio
  • Texas Valley Clinical Research · Weslaco, TX 78596Eduardo Luna · Principal investigatorMore trials in Weslaco

VA

  • Sovah Clinical Research-River District · Danville, VA 24541Stephan Jannach · Principal investigatorMore trials in Danville

WA

  • Central Washington Health Services Association d/b/a Confluence Health · Wenatchee, WA 98801Kathryn Eren · Principal investigatorMore trials in Wenatchee